

Doctor's Order Sheet CISplatin **25** - Gemcitabine **1000** Regimen:

CISplatin - Gemcitabine (Part I)

Adult Chemotherapy- Medical Oncology
Advanced Gallbladder Cancer and
Cholangiocarcinoma Therapy



CC1410 0012 06 2017

Name:		
HCN:		
Date of Birth:		

Allergies:			☐ No Known
Date:DD/MONTH/YYYY Cycle of Cycle Duration: 21		anned Administration Da	te:DD/MONTH/YYYYDD/MONTH/YYYY
MAY PROCEED WITH DOSES AS WRITTEN IF:			
 ANC greater than or equal to 1.0 X 10⁹/L, pl greater than or equal to 60 mL/minute, othe LFT's and Bilirubin assessed. 	•	•	X 10 ⁹ /L, Creatinine Clearance
PREMEDICATIONS:			
☐ Ondansetron 16 mg PO on Days 1 & 8			
☐ Dexamethasone 8 mg PO on Days 1 & 8			
☐ Other:			
HYDRATION/SUPPPORTIVE CARE:			
☐ Normal Saline 500 mLs IV pre-chemotherapy ov	er 60 minute	es	
Authorized Prescriber:	_ Date: _	DD/MONTH/YYYY	Time:
Authorized Prescriber's Signature:		ID #:	
Nurse's Name:	Date:	DD/MONTH/YYYY	_ Time:
Nurse's Signature:			

THIS IS A CONTROLLED DOCUMENT; PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION. USER WILL BE SOLELY RESPONSIBLE FOR VERIFYING ITS CURRENCY AND ACCURACY.

Page 1 of 2 CP-0012 2017/06



Nurse's Signature:

Doctor's Order Sheet CISplatin **25** - Gemcitabine **1000** Regimen:

CISplatin- Gemcitabine (Part II)

Name:

HCN:

Date of Birth:

Adult Chemotherapy- Medical Oncology Advanced Gallbladder Cancer and Cholangiocarcinoma Therapy Diagnosis

CC1410 0012 06 2017

vveight:kg Height:	cm	Body Surface Area	(BSA) =	
CHEMOTHERAPY (FOR HOSPITAL PHARMACY	') :			
☐ CISplatin 25 mg/m² X BSA = mg	ا IV in 250 mLs ا	IS infused at 1 mg/min	ute on Days 1 & 8	
☐ Dose modification: 25 mg/m² X BSA	% =	mg IV in 250 m	Ls NS infused at	
1 mg/minute on Days 1 & 8				
Gemcitabine 1000 mg/m² X BSA =	mg IV in 25	0 mLs NS over 30 min	utes on Days 1 & 8	
☐ Dose modification: 1000 mg/m² X BSA	% =	mg IV in 25	0 mLs NS	
over 30 minutes on Days 1 & 8				
Authorized Prescriber:	Date:	DD/MONTH/AAA/	Time:	
Authorized Prescriber's Signature:				
Nurse's Name:				

THIS IS A CONTROLLED DOCUMENT; PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION. USER WILL BE SOLELY RESPONSIBLE FOR VERIFYING ITS CURRENCY AND ACCURACY.

Page 2 of 2 CP-0012 2017/06